Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting

Author(s): A. Luscher, H. P. de Koning, P. Maser.

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 6 , 2007

Become EABM
Become Reviewer

Abstract:

Trypanosoma brucei rhodesiense and T. b. gambiense are the causative agents of sleeping sickness, a fatal disease that affects 36 countries in sub-Saharan Africa. Nevertheless, only a handful of clinically useful drugs are available. These drugs suffer from severe side-effects. The situation is further aggravated by the alarming incidence of treatment failures in several sleeping sickness foci, apparently indicating the occurrence of drug-resistant trypanosomes. Because of

Keywords: Trypanosoma brucei, sleeping sickness, functional genomics, drug target, chemotherapy, drug resistance

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 6
Year: 2007
Page: [555 - 567]
Pages: 13
DOI: 10.2174/138161207780162809
Price: $58

Article Metrics

PDF: 7